Symbolic imageAstraZeneca shares slide on Bristol Myers merger reports
Reports of talks on a roughly $400bn combination with Bristol Myers Squibb sent AstraZeneca shares down on Monday, while Bristol Myers shares climbed, according to the Wall Street Journal and Bloomberg. The Financial Times reported that AstraZeneca investors have raised concerns about the deal, which commentators say could face a difficult path.
To the edition